The North America Fractional Flow Reserve Market is expected to grow at a CAGR of 9.7% during 2019-2025. The US market dominated the North America FFR guidewires Market by Country in 2018, thereby, growing at a CAGR of 8.6 % during the forecast period.
In the regional market, North America accounted for a higher market share of the total industry sales in 2018. The region's dominance can be linked to beneficial government policies for the introduction of medical devices and the availability of well-developed healthcare infrastructure. Additionally, the higher number of mergers and acquisitions by key players are expected to maintain a high level of competition.
Companies operating in the market focus on launching innovative products and also expanding their business reach. For example, Abbott received the U.S. FDA approval In March 2019, for Resting Full-cycle Ratio (RFR) intravascular diagnostic test. This is a novel type of FFR physiologic assessment. The test aims to detect narrowing of the coronary arteries that indicate whether or whether not a stent is required.
Lesions with low fractional flow reserve percutaneous coronary intervention (PCI) increases long-term outcome and is clinically beneficial in patients with stable coronary artery disease relative to MT alone. At the time of coronary angiography, measuring fractional flow reserve (FFR) with a pressure wire determines coronary lesions which are responsible for severe ischemia. It also determines which patients most likely to benefit from PCI.
Coronary artery disease (CAD) is the most common form of heart disease, affecting the health of millions of people around the world. Coronary artery narrowing or stenosis in patients with CAD limits blood flow and reduces the amount of oxygen to the brain. Patients with CAD may receive advantages from the percutaneous coronary intervention (PCI), such as stenting partially occluded vessels, if stenosis causes inadequate oxygen supply to the heart. This condition is popularly termed as myocardial ischemia. The safety of deferring percutaneous coronary intervention (PCI) is tested by initial prospective randomized trials using FFR.
Increasing prevalence in the U.S. of coronary artery disease and diabetes serves well for the overall market. Cases of diabetes are on the rise due to the unhealthy eating habits of the country's population, which also contributes to obesity and related diseases. For example, the World Health Organization stated that there have been more than 1.9 billion obese adults in the U.S. during the year 2016. Furthermore, higher adoption of the fractional flow system in conjunction with OCT is likely to expand the consumer base in the near future for patients suffering from cardiovascular diseases, particularly in the U.S.
Free Valuable Insights: Fractional Flow Reserve Market in North America is expected to register a CAGR of 9.7% during the forecast period (2019-2025)
Based on Product, the market is segmented into FFR guidewires and FFR Monitoring Systems. Based on Application, the market is segmented into Multi-Vessel Coronary Artery Disease and Single-Vessel Coronary Artery Disease. The report also covers geographical segmentation of Fractional Flow Reserve market. The countries included in the report are USA, Canada, Mexico and Rest of North America.
Key companies profiled in the report include Medtronic PLC, Terumo Corporation, B. Braun Melsungen AG, General Electric (GE) Co, Siemens AG (Siemens Healthineers), Koninklijke Philips N.V., Boston Scientific Corporation, Abbott Laboratories, Bracco S.p.A. and Opsens, Inc.
Market Segmentation:
By Product
By Application
By Country
Companies Profiled
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 